Pipradrol API Manufacturers

General Description:

Pipradrol, identified by CAS number 467-60-7, is a notable compound with significant therapeutic applications. Pipradrol (Meratran) was initially developed in the 1950s as an antidepressant, however, the adverse effects associated with its use and its abuse potential led to its withdrawal and international regulation . Pipradrol was made illegal in many countries in 1970s because of its potential for abuse. It is currently classified under the Misuse of Drugs Act as a Class C substance . Experimentation with the drug and its derivatives for recreational purposes has led to many cases of acute toxicity and has been linked to three fatalities. The social and in particular acute clinical harms of pipradrol derivatives have led to their control under the Misuse of Drugs Act 1971 in the UK in 2012 . Interestingly, this drug has been studied for bactericidal properties, however, is not currently, used for this purpose . In addition to this, it has shown favorable effects in postpartum depressive symptoms .

Indications:

This drug is primarily indicated for: Used to manage fatigue and depression , , , . Used as an adjunct therapy in the management of obesity . Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Pipradrol undergoes metabolic processing primarily in: Rapidly metabolized, and not found in plasma approximately 4 hours post administration . This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Pipradrol are crucial for its therapeutic efficacy: Rapidly absorbed . The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Route of Elimination:

The elimination of Pipradrol from the body primarily occurs through: Quickly excreted in the urine (3.5%) and stool (5%) . Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Volume of Distribution:

Pipradrol is distributed throughout the body with a volume of distribution of: Distributed in the liver, kidney and brain tissue . This metric indicates how extensively the drug permeates into body tissues.

Clearance:

The clearance rate of Pipradrol is a critical factor in determining its safe and effective dosage: Rapidly cleared . It reflects the efficiency with which the drug is removed from the systemic circulation.

Pharmacodynamics:

Pipradrol exerts its therapeutic effects through: Pipradrol (Meratran) is a psychoactive agent and a central nervous system stimulant that has proven useful in the field of psychiatry . Pipradrol was initially used as an adjunct in the dietary management of obesity as well as for the management of dementia symptoms. Numerous reports have been made on the properties of pipradrol, demonstrating its favorable effects in the treatment of depression and fatigue in addition to a variety of other conditions including narcolepsy, spasmodic torticollis, schizophrenia and in geriatric practice . The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Pipradrol functions by: Pipradrol and pipradrol derivatives are norepinephrine and dopamine reuptake inhibitors . In a pharmacokinetic study, it was shown that pipradrol conditioned place preference (CPP) was blocked by selective D1 dopamine antagonist, implicating that a rewarding effect of pipradrol may involve the activation of D1 dopamine receptors. Pipradrol has a definite cerebral stimulating effect without affecting the blood pressure or respiration and has been used to counteract post-anaesthetic and chlorpromazine depression in man. Structurally related to phenylmethylamphetamine, a potent stimulant with a long half-life, pipradrol differs from amphetamine in that its action is more intense at higher centers, it does not exhibit pressor activity, there is no post-excitement depression, and this drug does not decrease appetite, as occurs with amphetamine . This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Classification:

Pipradrol belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups, classified under the direct parent group Diphenylmethanes. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Benzene and substituted derivatives class, specifically within the Diphenylmethanes subclass.

Categories:

Pipradrol is categorized under the following therapeutic classes: Central Nervous System Stimulants, Nervous System, Psychoanaleptics, Psychostimulants, Agents Used for ADHD and Nootropics. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.